SLDB 250117 10.00P (SLDB250117P10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

SLDB250117P10000

Watchlist

4.25
0.000.00%

15min DelayTrading Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Express News | Solid Biosciences Inc - Sgt-212 Dosing Expected to Initiate in Second Half of 2025
ReutersJan 21 08:31 ET
Express News | Solid Biosciences Receives FDA Fast Track Designation for Sgt-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
ReutersJan 21 08:30 ET
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia
Solid BiosciencesJan 21 00:00 ET
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Moomoo NewsJan 16 15:31 ET · Ratings
Solid Biosciences Announces Clinical Pipeline Updates: SGT-003 Tolerated In Duchenne Trial; SGT-212 FA Study For 2H 2025; SGT-501 IND Submission By H1 2025; $148.9M Cash Funding Through 2026
BenzingaJan 15 16:07 ET
Express News | Solid Biosciences Inc - Cash and Investments Expected to Fund Key Strategic Priorities Into 2026
ReutersJan 15 16:06 ET

Comments

Stock_Drift

Jan 21 07:57

$Solid Biosciences (SLDB.US)$

Jaguar8

Jan 21 07:36

NEWS

$Solid Biosciences (SLDB.US)$
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia
Tuesday, 21st January at 8:30 am
- Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation -
CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB), a life sciences company developing precision genetic medicines for neurom...

Jaguar8

Jan 15 15:05

NEWS

$Solid Biosciences (SLDB.US)$
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
Wednesday, 15th January at 4:05 pm
- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
- FA: First-in-human clinical study of SGT-212 utilizing a dual route of ...

Blick

Jan 8 03:31

$Solid Biosciences (SLDB.US)$ 🤔

Jaguar8

Jan 7 20:00

⚫️ Watchlist JANUARY 8,2025, Wednesday NFA

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. NEVER be a blind follower.
LASTLY, If y...